CooperCompanies

Fiscal 2023 financial guidance

		FY23 Guidance*	Organic Growth vs. FY22
Sales	Total	\$3,512 - \$3,569	7% - 9%
	CooperVision	\$2,365 - \$2,400	8% - 10%
	CooperSurgical	\$1,147 - \$1,169	5% - 7%
EPS	Non-GAAP	\$12.66 - \$12.96	



Note: Sales \$ in millions; Organic growth excludes the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures, or discontinuations that occurred in the comparable period. Non-GAAP and organic – a reconciliation of these measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on the Company's website: www.coopercos.com.

*Guidance updated 6/1/23. FY23 financial guidance does not include the Cook Medical Reproductive Health acquisition announced on 2/7/22